Abstract
Hepatocyte growth factor (HGF) is a mesenchyme-derived pleiotropic factor that regulates cell growth, cell motility, and morphogenesis of various types of cells and is, thus, considered a humoral mediator of epithelial-mesenchymal interactions. Although HGF was originally identified as a potent mitogen for hepatocytes, HGF is now well known as an angiogenic growth factor. Because the presence of its specific receptor, c-met, is observed in vascular cells and cardiac myocytes, the cardiovascular HGF-met system has been a center of interest. Malatino et al1 suggested that an increase in circulating HGF might be compensated to myocardial damage in dialysis patients, because our recent report demonstrated that HGF reduced cardiac fibrosis through the inhibition of endothelial mesenchymal transition and the transformation of fibroblasts to myofibroblasts.2 We agree with their hypothesis that circulating HGF might be increased to attenuate the cardiovascular damage. In various pathophysiological conditions, such as hypertension, peripheral …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
